Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP for Prevention of Adhesion Reformation in Asherman Syndrome
NCT06608407Enrolling by invitation
- Sponsor
- Fuxing Hospital, Capital Medical University
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Randomised, single-blind trial of autologous platelet-rich plasma in Asherman syndrome (IUA) (2 arms), sponsored by Fuxing Hospital, Capital Medical University. Primary endpoints: American Fertility Society Score at 8 weeks and Endometrial Thickness at 3 months. Started Oct 2023; status: enrolling by invitation.
02
Drugs
autologous platelet-rich plasma
03
Conditions
Asherman syndrome (IUA)
Beyond the preview
Go deeper on NCT06608407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608407.